AnaptysBio Inc

+0.21 (+0.82%)
Mergers / Acquisitions

DRI Healthcare Trust Announces Acquisition Of A Royalty Interest In Zejula

Published: 09/12/2022 11:51 GMT
AnaptysBio Inc (ANAB) - Dri Healthcare Trust Announces Acquisition of a Royalty Interest in Zejula®, Currently Approved for the Treatment of Ovarian Cancer With Additional Indications Under Development.
Dri Healthcare Trust - Transaction Entitles Dri to a Net 0.5% Royalty on Worldwide Net Sales of Zejula by Gsk Plc.
Dri Healthcare - to Be Entitled to Receive Qtrly Royalty Payments on One-quarter Lag Based on Sales From July 1, 2022, to Get First Payment in Q4 2022.
Dri Healthcare Trust - Royalty Term is Expected to Continue for at Least Another 10 Years Worldwide.